
ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval
13.11.2026
0:00
1:30
In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.
Weitere Episoden von „Applied Clinical Trials“



Verpasse keine Episode von “Applied Clinical Trials” und abonniere ihn in der kostenlosen GetPodcast App.








